Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.57 |
| ▸ | ITGAV | P06756 | 20/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.56 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.46 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547445 | 0.91 | ITGB3 (0.67) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL2928639 | 0.90 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL8347781 | 0.83 | ITGB3 (0.66) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL2906491 | 0.81 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL2919045 | 0.81 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL2902148 | 0.79 | ITGB3 (0.84) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2906028 | 0.78 | ITGB3 (0.83) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2906682 | 0.77 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL20157714 | 0.75 | ITGAV (0.74) | ITGB3ITGAVITGA2BITGB6ITGB1 | |
| SCHEMBL16299424 | 0.75 | OGA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| EP-2217569-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | ITGA5, ITGA1, ITGB5 | ITGB3 13/4885ITGAV 8/4885ITGA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.